SynthesisPloS one2025
Effect of different concentrations of heparin-locking solution for central venous catheters in hemodialysis patients: A systematic review and meta-analysis.
Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of different concentrations of heparin-locking solution for central venous catheters (CVC) in hemodialysis patients is varied. Regarding the optimal concentration of heparin-locking solution, there is no definitive consensus based on evidence.
objectiveTo investigate the efficacy and safety of different concentrations of heparin for CVC locking in hemodialysis patients.
methodsWe searched PubMed, Embase, Web of science, the Cochrane Library and Clinical Trial Database (clinicaltrials.gov) from establishment of each database to September 19, 2024 for randomized control trials (RCTs), non-randomized control trials (NRCTs) and cohort study of heparin-locking solution for CVC in hemodialysis patients aged ≥ 18 years. Outcome data regarding catheter occlusion, hemodialysis blood flow, bleeding-related complications, catheter-related infection, and catheter retention time were extracted and pooled from selected studies. The quality of included RCTS, cohort studies, and NRCT were assessed using bias risk tools recommended in the Cochrane Handbook. A fixed-effect model was used to calculate pooled odds ratios or mean differences with 95% confidence intervals.
resultsThree RCTs, three cohort studies and one NRCT involving 946 hemodialysis patients were included. Heparin-locking solution of 1000 U/ml reduces the occurrence of bleeding related complications (OR = 0.20, 95%CI: 0.05-0.79, P = 0.02) compared to 5000 U/ml and 10000 U/ml. No significant difference was observed in hemodialysis blood flow (MD = -6.95, 95% CI: -14.41- 0.51, P = 0.07), catheter occlusion (OR = 0.89, 95% CI = 0.60-1.33, P = 0.58), catheter retention time (MD = -0.16, 95% CI: -1.98 - 1.67, P = 0.87), and catheter-related infection (OR = 0.60, 95%CI: 0.31-1.19, P = 0.14).
conclusionOur findings suggest that a heparin-locking solution at a concentration of 1000 U/ml for central venous catheters (CVC) in hemodialysis patients may reduce the incidence of bleeding-related complications, without impacting the rates of catheter occlusion, hemodialysis blood flow, catheter retention time, or catheter-related infections. However, due to the limited number of included studies, high-quality randomized controlled trials and cohort studies with long-term follow-up are warranted to further validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.